Intrathecal ketorolac in dogs and rats

Tony L. Yaksh, Kjersti A. Horais, Nicolle Tozier, Michael Rathbun, Phil Richter, Steve Rossi, Marjorie Grafe, Chuanyao Tong, Carol Meschter, J. Mark Cline, James Eisenach

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

This study was conducted to assess spinal safety of the cyclooxygenase inhibitor ketorolac in dogs and rats. Beagle dogs were prepared with lumbar intrathecal catheters and received continuous spinal infusions of 5 mg/ml ketorolac (N = 6), 0.5 mg/ml ketorolac (N = 8), or saline vehicle (N = 6) at 50 μl/h (1.2 ml/day) for 28 days. No systematic drug or dose-related changes were observed in motor function, heart rate, or blood pressure. Histological examination revealed a mild pericatheter reaction in all groups with no drug or dose related effect upon spinal pathology at the lumbar site of highest drug concentration. Cisternal CSF protein was elevated for all treatment groups at necropsy, and cisternal glucose was within normal range for all treatment groups, though three dogs displayed decreases in cisternal glucose. Significant reductions in hematocrit were noted, and increased incidence of gastric bleeding at necropsy was observed in animals receiving ketorolac. Intrathecal ketorolac kinetics revealed a biphasic clearance: t1/2s = 10.3 and 53 min, respectively. After initiation of infusion (0.5 mg and 5 mg/ml/50 μl/h), lumbar CSF concentrations of ketorolac were 3.8 and 52.7 μg/ml, respectively. Bolus and continuous infusion of intrathecal ketorolac resulted in significant reduction of lumbar CSF PGE2 concentrations. In rats, with intrathecal catheters, four daily bolus deliveries of saline or ketorolac (5 mg/ml/10 μl) had no effect upon spinal histology or upon spinal cord blood flow. These data indicate that intrathecal ketorolac in two species at the dose/concentrations employed does not induce evident spinal pathology but diminishes spinal prostaglandin release.

Original languageEnglish (US)
Pages (from-to)322-334
Number of pages13
JournalToxicological Sciences
Volume80
Issue number2
DOIs
StatePublished - Aug 2004

Fingerprint

Ketorolac
Rats
Dogs
Catheters
Pathology
Spinal Infusions
Pharmaceutical Preparations
Glucose
Histology
Cyclooxygenase Inhibitors
Blood pressure
Fetal Blood
Hematocrit
Dinoprostone
Prostaglandins
Spinal Cord
Stomach
Reference Values
Animals
Blood

Keywords

  • COX
  • Cyclo-oxygenase
  • Nonsteroidal anti-inflammatory drug (NSAID)
  • Prostaglandin
  • Spinal

ASJC Scopus subject areas

  • Toxicology

Cite this

Yaksh, T. L., Horais, K. A., Tozier, N., Rathbun, M., Richter, P., Rossi, S., ... Eisenach, J. (2004). Intrathecal ketorolac in dogs and rats. Toxicological Sciences, 80(2), 322-334. https://doi.org/10.1093/toxsci/kfh168

Intrathecal ketorolac in dogs and rats. / Yaksh, Tony L.; Horais, Kjersti A.; Tozier, Nicolle; Rathbun, Michael; Richter, Phil; Rossi, Steve; Grafe, Marjorie; Tong, Chuanyao; Meschter, Carol; Cline, J. Mark; Eisenach, James.

In: Toxicological Sciences, Vol. 80, No. 2, 08.2004, p. 322-334.

Research output: Contribution to journalArticle

Yaksh, TL, Horais, KA, Tozier, N, Rathbun, M, Richter, P, Rossi, S, Grafe, M, Tong, C, Meschter, C, Cline, JM & Eisenach, J 2004, 'Intrathecal ketorolac in dogs and rats', Toxicological Sciences, vol. 80, no. 2, pp. 322-334. https://doi.org/10.1093/toxsci/kfh168
Yaksh TL, Horais KA, Tozier N, Rathbun M, Richter P, Rossi S et al. Intrathecal ketorolac in dogs and rats. Toxicological Sciences. 2004 Aug;80(2):322-334. https://doi.org/10.1093/toxsci/kfh168
Yaksh, Tony L. ; Horais, Kjersti A. ; Tozier, Nicolle ; Rathbun, Michael ; Richter, Phil ; Rossi, Steve ; Grafe, Marjorie ; Tong, Chuanyao ; Meschter, Carol ; Cline, J. Mark ; Eisenach, James. / Intrathecal ketorolac in dogs and rats. In: Toxicological Sciences. 2004 ; Vol. 80, No. 2. pp. 322-334.
@article{d487fab69c444b86875c677e3aea2853,
title = "Intrathecal ketorolac in dogs and rats",
abstract = "This study was conducted to assess spinal safety of the cyclooxygenase inhibitor ketorolac in dogs and rats. Beagle dogs were prepared with lumbar intrathecal catheters and received continuous spinal infusions of 5 mg/ml ketorolac (N = 6), 0.5 mg/ml ketorolac (N = 8), or saline vehicle (N = 6) at 50 μl/h (1.2 ml/day) for 28 days. No systematic drug or dose-related changes were observed in motor function, heart rate, or blood pressure. Histological examination revealed a mild pericatheter reaction in all groups with no drug or dose related effect upon spinal pathology at the lumbar site of highest drug concentration. Cisternal CSF protein was elevated for all treatment groups at necropsy, and cisternal glucose was within normal range for all treatment groups, though three dogs displayed decreases in cisternal glucose. Significant reductions in hematocrit were noted, and increased incidence of gastric bleeding at necropsy was observed in animals receiving ketorolac. Intrathecal ketorolac kinetics revealed a biphasic clearance: t1/2s = 10.3 and 53 min, respectively. After initiation of infusion (0.5 mg and 5 mg/ml/50 μl/h), lumbar CSF concentrations of ketorolac were 3.8 and 52.7 μg/ml, respectively. Bolus and continuous infusion of intrathecal ketorolac resulted in significant reduction of lumbar CSF PGE2 concentrations. In rats, with intrathecal catheters, four daily bolus deliveries of saline or ketorolac (5 mg/ml/10 μl) had no effect upon spinal histology or upon spinal cord blood flow. These data indicate that intrathecal ketorolac in two species at the dose/concentrations employed does not induce evident spinal pathology but diminishes spinal prostaglandin release.",
keywords = "COX, Cyclo-oxygenase, Nonsteroidal anti-inflammatory drug (NSAID), Prostaglandin, Spinal",
author = "Yaksh, {Tony L.} and Horais, {Kjersti A.} and Nicolle Tozier and Michael Rathbun and Phil Richter and Steve Rossi and Marjorie Grafe and Chuanyao Tong and Carol Meschter and Cline, {J. Mark} and James Eisenach",
year = "2004",
month = "8",
doi = "10.1093/toxsci/kfh168",
language = "English (US)",
volume = "80",
pages = "322--334",
journal = "Toxicological Sciences",
issn = "1096-6080",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Intrathecal ketorolac in dogs and rats

AU - Yaksh, Tony L.

AU - Horais, Kjersti A.

AU - Tozier, Nicolle

AU - Rathbun, Michael

AU - Richter, Phil

AU - Rossi, Steve

AU - Grafe, Marjorie

AU - Tong, Chuanyao

AU - Meschter, Carol

AU - Cline, J. Mark

AU - Eisenach, James

PY - 2004/8

Y1 - 2004/8

N2 - This study was conducted to assess spinal safety of the cyclooxygenase inhibitor ketorolac in dogs and rats. Beagle dogs were prepared with lumbar intrathecal catheters and received continuous spinal infusions of 5 mg/ml ketorolac (N = 6), 0.5 mg/ml ketorolac (N = 8), or saline vehicle (N = 6) at 50 μl/h (1.2 ml/day) for 28 days. No systematic drug or dose-related changes were observed in motor function, heart rate, or blood pressure. Histological examination revealed a mild pericatheter reaction in all groups with no drug or dose related effect upon spinal pathology at the lumbar site of highest drug concentration. Cisternal CSF protein was elevated for all treatment groups at necropsy, and cisternal glucose was within normal range for all treatment groups, though three dogs displayed decreases in cisternal glucose. Significant reductions in hematocrit were noted, and increased incidence of gastric bleeding at necropsy was observed in animals receiving ketorolac. Intrathecal ketorolac kinetics revealed a biphasic clearance: t1/2s = 10.3 and 53 min, respectively. After initiation of infusion (0.5 mg and 5 mg/ml/50 μl/h), lumbar CSF concentrations of ketorolac were 3.8 and 52.7 μg/ml, respectively. Bolus and continuous infusion of intrathecal ketorolac resulted in significant reduction of lumbar CSF PGE2 concentrations. In rats, with intrathecal catheters, four daily bolus deliveries of saline or ketorolac (5 mg/ml/10 μl) had no effect upon spinal histology or upon spinal cord blood flow. These data indicate that intrathecal ketorolac in two species at the dose/concentrations employed does not induce evident spinal pathology but diminishes spinal prostaglandin release.

AB - This study was conducted to assess spinal safety of the cyclooxygenase inhibitor ketorolac in dogs and rats. Beagle dogs were prepared with lumbar intrathecal catheters and received continuous spinal infusions of 5 mg/ml ketorolac (N = 6), 0.5 mg/ml ketorolac (N = 8), or saline vehicle (N = 6) at 50 μl/h (1.2 ml/day) for 28 days. No systematic drug or dose-related changes were observed in motor function, heart rate, or blood pressure. Histological examination revealed a mild pericatheter reaction in all groups with no drug or dose related effect upon spinal pathology at the lumbar site of highest drug concentration. Cisternal CSF protein was elevated for all treatment groups at necropsy, and cisternal glucose was within normal range for all treatment groups, though three dogs displayed decreases in cisternal glucose. Significant reductions in hematocrit were noted, and increased incidence of gastric bleeding at necropsy was observed in animals receiving ketorolac. Intrathecal ketorolac kinetics revealed a biphasic clearance: t1/2s = 10.3 and 53 min, respectively. After initiation of infusion (0.5 mg and 5 mg/ml/50 μl/h), lumbar CSF concentrations of ketorolac were 3.8 and 52.7 μg/ml, respectively. Bolus and continuous infusion of intrathecal ketorolac resulted in significant reduction of lumbar CSF PGE2 concentrations. In rats, with intrathecal catheters, four daily bolus deliveries of saline or ketorolac (5 mg/ml/10 μl) had no effect upon spinal histology or upon spinal cord blood flow. These data indicate that intrathecal ketorolac in two species at the dose/concentrations employed does not induce evident spinal pathology but diminishes spinal prostaglandin release.

KW - COX

KW - Cyclo-oxygenase

KW - Nonsteroidal anti-inflammatory drug (NSAID)

KW - Prostaglandin

KW - Spinal

UR - http://www.scopus.com/inward/record.url?scp=4344563319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344563319&partnerID=8YFLogxK

U2 - 10.1093/toxsci/kfh168

DO - 10.1093/toxsci/kfh168

M3 - Article

C2 - 15141096

AN - SCOPUS:4344563319

VL - 80

SP - 322

EP - 334

JO - Toxicological Sciences

JF - Toxicological Sciences

SN - 1096-6080

IS - 2

ER -